Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.9506 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,089
Open 0.9506
Bid (Size) 0.9410 (1)
Ask (Size) 0.9800 (2)
Prev. Close 0.9506
Today's Range 0.9506 - 0.9506
52wk Range 0.8000 - 2.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire

Performance

YTD
-34.4%
-34.4%
1 Month
+10.7%
+10.7%
3 Month
+2.9%
+2.9%
6 Month
-37.9%
-37.9%
1 Year
-57.2%
-57.2%

More News

Read More
Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
From Clearmind Medicine Inc.
Via GlobeNewswire
Stocks Under $1 To Watch: $NITO, $SPRC, $PNPNF, $NCNA, $PRSO – Multi-Sectors Momentum Building more inside…
Via AB Newswire
Topics Intellectual Property
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
From Clearmind Medicine Inc.
Via GlobeNewswire
Which stocks have an unusual volume on Monday?
Via Chartmill
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
From Clearmind Medicine Inc.
Via GlobeNewswire
Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves
Via AB Newswire
Topics Intellectual Property

Frequently Asked Questions

Is Clearmind Medicine Inc. - Common Shares publicly traded?
Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.
What exchange does Clearmind Medicine Inc. - Common Shares trade on?
Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?
The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market
What is the current price of Clearmind Medicine Inc. - Common Shares?
The current price of Clearmind Medicine Inc. - Common Shares is 0.9506
When was Clearmind Medicine Inc. - Common Shares last traded?
The last trade of Clearmind Medicine Inc. - Common Shares was at 07/11/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.